Andere Sprachen Eris Lifesciences Limited

Aktien

A2DU61

INE406M01024

ERIS

Verzögert NSE India S.E. Andere Börsenplätze 08:23:33 03.06.2024			% 5 Tage	% 1. Jan.
906,3 ^INR	-1,07 %		+2,76 %	-0,38 %

22.05.	Eris Lifesciences verzeichnet Zuwächse beim konsolidierten Nettogewinn im 4.	MT
21.05.	Eris Lifesciences erhält Zustimmung des Vorstands zur Aufnahme von bis zu 12,50 Mrd. INR durch Anleiheverkauf	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit	22.05.
Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale	21.05.
Transcript : Eris Lifesciences Limited, Q4 2024 Earnings Call, May 21, 2024	21.05.
Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	18.04.
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03.04.
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15.03.
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call	14.03.
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14.03.
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14.03.
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16.02.
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15.02.
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13.02.
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024	13.02.
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13.02.
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08.02.
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10.11.
Indian shares set to open higher tracking Asian peers	09.11.
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08.11.
Transcript : Eris Lifesciences Limited, Q2 2024 Earnings Call, Nov 08, 2023	08.11.
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eris Lifesciences Limited

Aktien

A2DU61

INE406M01024

ERIS

Andere Sprachen

Filter